These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32803532)

  • 1. Clinical phenotypes combined with saturation genome editing identifying the pathogenicity of BRCA1 variants of uncertain significance in breast cancer.
    Wan Q; Hu L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    Fam Cancer; 2021 Apr; 20(2):85-95. PubMed ID: 32803532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
    So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
    Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Concolino P; Gelli G; Rizza R; Costella A; Scambia G; Capoluongo E
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined annotation-dependent depletion score for BRCA1/2 variants in patients with breast and/or ovarian cancer.
    Nakagomi H; Mochizuki H; Inoue M; Hirotsu Y; Amemiya K; Sakamoto I; Nakagomi S; Kubota T; Omata M
    Cancer Sci; 2018 Feb; 109(2):453-461. PubMed ID: 29215753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reclassification of
    Lee JS; Oh S; Park SK; Lee MH; Lee JW; Kim SW; Son BH; Noh DY; Lee JE; Park HL; Kim MJ; Cho SI; Lee YK; Park SS; Seong MW
    J Med Genet; 2018 Dec; 55(12):794-802. PubMed ID: 30415210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes.
    Billaud A; Chevalier LM; Augereau P; Frenel JS; Passot C; Campone M; Morel A
    Genome Med; 2021 Nov; 13(1):174. PubMed ID: 34749799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort.
    Liu Y; Wang H; Wang X; Liu J; Li J; Wang X; Zhang Y; Bai Z; Zhou Q; Wu Y; Shen Y; Weng X; Liu F; Guo J; Di L; Gires O; Zhang Z; Chen Y; Wang H
    J Hematol Oncol; 2021 Jan; 14(1):18. PubMed ID: 33461583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).
    Lindor NM; Guidugli L; Wang X; Vallée MP; Monteiro AN; Tavtigian S; Goldgar DE; Couch FJ
    Hum Mutat; 2012 Jan; 33(1):8-21. PubMed ID: 21990134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach.
    Caputo SM; Golmard L; Léone M; Damiola F; Guillaud-Bataille M; Revillion F; Rouleau E; Derive N; Buisson A; Basset N; Schwartz M; Vilquin P; Garrec C; Privat M; Gay-Bellile M; Abadie C; Abidallah K; Airaud F; Allary AS; Barouk-Simonet E; Belotti M; Benigni C; Benusiglio PR; Berthemin C; Berthet P; Bertrand O; Bézieau S; Bidart M; Bignon YJ; Birot AM; Blanluet M; Bloucard A; Bombled J; Bonadona V; Bonnet F; Bonnet-Dupeyron MN; Boulaire M; Boulouard F; Bouras A; Bourdon V; Brahimi A; Brayotel F; Bressac de Paillerets B; Bronnec N; Bubien V; Buecher B; Cabaret O; Carriere J; Chiesa J; Chieze-Valéro S; Cohen C; Cohen-Haguenauer O; Colas C; Collonge-Rame MA; Conoy AL; Coulet F; Coupier I; Crivelli L; Cusin V; De Pauw A; Dehainault C; Delhomelle H; Delnatte C; Demontety S; Denizeau P; Devulder P; Dreyfus H; d'Enghein CD; Dupré A; Durlach A; Dussart S; Fajac A; Fekairi S; Fert-Ferrer S; Fiévet A; Fouillet R; Mouret-Fourme E; Gauthier-Villars M; Gesta P; Giraud S; Gladieff L; Goldbarg V; Goussot V; Guibert V; Guillerm E; Guy C; Hardouin A; Heude C; Houdayer C; Ingster O; Jacquot-Sawka C; Jones N; Krieger S; Lacoste S; Lallaoui H; Larbre H; Laugé A; Le Guyadec G; Le Mentec M; Lecerf C; Le Gall J; Legendre B; Legrand C; Legros A; Lejeune S; Lidereau R; Lignon N; Limacher JM; Doriane Livon ; Lizard S; Longy M; Lortholary A; Macquere P; Mailliez A; Malsa S; Margot H; Mari V; Maugard C; Meira C; Menjard J; Molière D; Moncoutier V; Moretta-Serra J; Muller E; Nevière Z; Nguyen Minh Tuan TV; Noguchi T; Noguès C; Oca F; Popovici C; Prieur F; Raad S; Rey JM; Ricou A; Salle L; Saule C; Sevenet N; Simaga F; Sobol H; Suybeng V; Tennevet I; Tenreiro H; Tinat J; Toulas C; Turbiez I; Uhrhammer N; Vande Perre P; Vaur D; Venat L; Viellard N; Villy MC; Warcoin M; Yvard A; Zattara H; Caron O; Lasset C; Remenieras A; Boutry-Kryza N; Castéra L; Stoppa-Lyonnet D
    Am J Hum Genet; 2021 Oct; 108(10):1907-1923. PubMed ID: 34597585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional analysis of clinical
    Toh MR; Chong ST; Chan SH; Low CE; Ishak NDB; Lim JQ; Courtney E; Ngeow J
    Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 31371347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating risks for variants of unknown significance according to their predicted pathogenicity classes with application to BRCA1.
    Dowty JG; Lee E; McKean-Cowdin R; Henderson BE; Bernstein L; Ursin G; Hopper JL
    Breast Cancer Res Treat; 2014 Feb; 144(1):171-7. PubMed ID: 24481681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance.
    Langerud J; Jarhelle E; Van Ghelue M; Ariansen SL; Iversen N
    Hum Genomics; 2018 Nov; 12(1):51. PubMed ID: 30458859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of VUS reclassification in a single-centre series from application of ACMG/AMP classification rules specified for
    Innella G; Ferrari S; Miccoli S; Luppi E; Fortuno C; Parsons MT; Spurdle AB; Turchetti D
    J Med Genet; 2024 Apr; 61(5):483-489. PubMed ID: 38160042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in classification of genetic variants in BRCA1 and BRCA2.
    Kast K; Wimberger P; Arnold N
    Arch Gynecol Obstet; 2018 Feb; 297(2):279-280. PubMed ID: 29302806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.
    Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high-throughput functional complementation assay for classification of BRCA1 missense variants.
    Bouwman P; van der Gulden H; van der Heijden I; Drost R; Klijn CN; Prasetyanti P; Pieterse M; Wientjens E; Seibler J; Hogervorst FB; Jonkers J
    Cancer Discov; 2013 Oct; 3(10):1142-55. PubMed ID: 23867111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
    Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
    BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.